See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

Leqembi (lecanemab-irmb) has potential interactions with other medications. These interactions could cause harmful effects. An interaction can occur because one substance causes another substance ...

BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that the interim safety review of the clinical Phase 2a study EXIST ...

The National Institute for Health and Care Excellence (NICE) has refused the 'miracle' drugs lecanemab and donanemab for use ...

Two new drugs targeting early-stage Alzheimer’s disease are expected to be put into clinical use as soon as Thursday next ...

The U.S. Food and Drug Administration has cleared Fujirebio Diagnostics' blood test to diagnose Alzheimer's disease, the regulator said on Friday, making the device the first of its kind to detect the ...

Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for b ...

BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) today welcomes investors, analysts and financial media to the company's Capital Markets Day.

Content by Health System. June is Alzheimer’s and Brain Awareness Month, which means there’s no better time to focus on your ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $190.82, a high estimate of ...

A new Fujirebio Diagnostics blood test identifies beta-amyloid, a brain plaque that is a key marker for Alzheimer’s disease.

Leqembi (lecanemab-irmb) is a prescription drug that’s used to treat Alzheimer’s disease. It comes as a liquid solution that healthcare professionals administer as an intravenous (IV ...